Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)

Sponsor
Insel Gruppe AG, University Hospital Bern
Study ID
NCT00413829
Phase
PHASE2
Status
Completed

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is an evaluation of the short term effects on CNV perfusion of a same-day administration of photodynamic therapy (PDT) with Visudyne® and an intravitreal injection of Lucentis® (ranibizumab, 0.3 mg). An evaluation of the short term effects on CNV perfusion of this combined treatment is needed for better understanding of treatment effects.

Key Dates

First listed
Dec 20, 2006
Start date
Oct 31, 2006
Status verified
Jan 2010
Primary completion
May 31, 2007
Completion
Mar 31, 2008

Study Design

Enrollment
20 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: 1

Primary Outcome Measure

incidence of CNV closure one week after combined therapy as assessed with high speed ICG angiography [ Time Frame: 24 months ]

Related Studies